Pricing Log in Create free account
Friday 6 November 2026 Export NUTX’s income statement to Excel — free account

Nutex Health Inc.

NUTX Healthcare Medical Care Facilities

Nutex Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $875.3 million, up 82.4% from fiscal 2024.

Revenue
−13.6%
EPS
+424.8%
Free cash flow
+19.4%
Total debt
−1.69%

Quarter to June 2026, against a year earlier

182.25 11.39 −5.88%
Market cap
$1.3B
P/E
7.4×
Fwd P/E
7.3×
Dividend yield
—
F-score
7/9
Altman Z
3.27
Beneish M
−2.54
Dividend safety
41/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.05
Sold, $m 0.04
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 4 — — — — — — — —
Sell — — — — — — — — — 1 — —
Insider Ownership 33.05%

Capital & Financial Ratios $m

Size
Market Cap 1,330.00
Revenue ttm 846.72
Net income ttm 272.49
Free cash flow ttm 274.17
Net debt Q 93.00
Valuation
P/E 7.42
Forward P/E 7.31
Price / sales 1.58
Forward P/S Powerpack
Price / FCF 4.88
Price / book 2.64
Financial health
Current ratio Q 5.00 (at or above 1.5: strong)
Debt / equity Q 0.59
Interest coverage Q 26.06
Growth
Revenue growth Q −13.62% (below 0%: shrinking)
Operating income growth Q +261.41% (above 0%: growing)
EPS, this year +161.13% (at or above 15%: strong)
EPS, next year A −0.18% (below 0%: weak)
Revenue, next year A −0.54% (below 0%: weak)
EPS, past 5 yrs −17.13% (below 0%: weak)
EPS, next 5 yrs A +36.68% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 1.9×; over the ten years it ranged from 0.2× in 2021 to 14.5× in 2022.
P/E against its own 10 years 32.54%
10-year low 10-year high
P/S against its own 10 years 55.42%
10-year low 10-year high
P/B against its own 10 years 57.67%
10-year low 10-year high
EV/Sales against its own 10 years 44.32%
10-year low 10-year high
EV/FCF against its own 10 years 18.36%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 22 44 186 207
Receivables 63 236 325 357
Inventory 3 3 3 4
Other — — — —
91 292 539 586
2023 2024 2025 Q'26
Payables 25 10 49 10
ST’ Debt 14 18 14 0
Other — — — —
58 154 158 117

Compound Annual Growth %

10y 5y 3y
Sales — 26.14% 58.62%
Cash Flow — 23.41% 69.88%
Earnings — (7.75%) 0.00%
Book Value — 0.00% 52.10%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 5.26 Actual 9.58

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY23 −3.00 −1.50 Beat by 1.50
Q2 FY23 −1.50 −1.50 Met by 0.00
Q3 FY23 −1.50 −1.50 Met by 0.00
Q2 FY26 5.26 9.58 Beat by 4.32
Q3 FY26 5.53 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 6.52 9.58 — — —
’25 3.33 (2.95) 7.76 1.61 10.48
’24 (0.10) (0.07) (1.72) 11.12 9.71
’23 (1.50) (0.97) (1.25) (7.50) (10.49)
’22 6.28 (4.50) (97.45) (3.00) (100.45)
’21 (36.20) 7.51 18.84 52.48 33.55
’20 (35.98) 7.33 50.83 14.86 26.81
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 216 211 — — —
’25 212 244 268 152 875
’24 67 76 79 258 480
’23 56 59 63 70 248
’22 79 58 28 54 219
’21 2 63 118 149 332
’20 0 0 0 273 274
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 76 34 — — —
’25 51 27 100 70 248
’24 3 13 7 0 23
’23 1 0 2 (2) 1
’22 36 18 (7) 5 51
’21 (1) 103 24 46 173
’20 (1) 0 0 88 87
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 74 32 — — —
’25 51 27 99 69 246
’24 2 13 6 0 21
’23 (3) (3) (1) (1) (8)
’22 27 10 (13) 12 36
’21 (1) 82 21 35 137
’20 (1) 0 0 27 25
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 0 1 1 274 332 219 248 480 875 847 +273.3% 871 960 1,018 +5.2%
Gross margin, % — (31.47) 62.87 39.23 57.51 54.08 7.03 14.04 40.89 50.76 51.26 +82.2 pt
EBT 0 (6) (1) (7) 146 169 (420) (48) 110 245 343 n/m
EBT margin, % 0.00 (25,894.40) (69.50) (520.82) 53.18 51.12 (191.36) (19.58) 22.88 27.97 40.57 +28.0 pt
Net income (7) 1 (1) (7) 146 169 (433) (43) 95 180 272 n/m
Per share, $
Per share, $ Revenue 0.00 21.09 119.91 56.46 69.31 83.85 51.81 56.18 94.28 137.59 123.23 n/m
Earnings (14,038.98) 529.18 (83.67) (294.06) 26.81 33.55 (100.45) (10.49) 10.25 11.13 26.22 n/m
Cash flow (548.40) (649.64) (42.11) (166.96) 21.92 43.86 11.96 0.29 4.55 39.00 40.70 n/m
Capex 0.00 0.00 0.00 (3.47) (15.48) (9.34) (3.46) (2.15) (0.45) (0.40) (0.79) n/m
Free cash flow (548.40) (649.64) (42.11) (170.43) 6.45 34.52 8.50 (1.87) 4.10 38.61 39.90 n/m
Book value (11,738.80) 2,153.64 (131.35) 76.79 (0.29) 48.45 28.43 17.94 37.03 66.56 73.83 n/m
Shares, m 0 0 0 0 4 4 4 4 5 6 7 +185.8%
Valuation, ×
Valuation, × P/E — 0.37 0.37 0.00 5.87 14.50 0.00 0.00 3.19 15.34 7.42 4.4
P/S — 3.81 3.81 5.31 3.14 7.37 5.76 0.53 0.34 1.20 1.58 3.5
P/B — 13.05 13.05 3.91 0.00 12.75 10.50 1.67 0.86 2.47 2.64 6.5
EV/Sales — 4.25 4.25 6.74 3.14 7.73 6.71 1.47 0.87 1.33 1.69 4.1
EV/FCF — (3.86) (3.86) (2.23) 33.76 34.02 40.89 (44.25) 20.03 4.72 5.22 8.8
Cash, $m
Cash, $m Operating cash flow 0 (1) 0 (4) 87 173 51 1 23 248 280 n/m
Capex — — — 0 (61) (37) (15) (9) (2) (3) (5) +76.3%
Free cash flow 0 (1) 0 (4) 25 137 36 (8) 21 246 274 n/m
Balance, $m
Balance, $m Working capital (6) (1) (1) (3) (1) 116 43 33 138 381 468 n/m
Net debt 0 0 1 1 0 119 208 232 256 126 93 +145.1%
Shareholders’ equity (6) 2 (1) 2 (1) 192 120 79 189 423 507 n/m
Returns, %
Returns, % ROA (2,910.02) 30.32 (50.29) (199.29) 3,088.42 67.17 (102.80) (11.03) 9.89 9.00 19.93 +2,919.0 pt
ROIC 0.00 (132.11) 0.00 (137.79) 0.00 34.30 (77.50) (6.38) 18.36 31.34 37.92 +31.3 pt
ROE 0.00 (33.26) (218.01) (3,942.66) 29,249.21 139.24 (272.38) (45.92) 38.93 23.13 42.63 +23.1 pt
People
People Employees 18 6 6 12 14 24 1,150 800 800 944 — +55.3%
Revenue/emp, $m 0.00 0.00 0.23 0.11 19.57 13.81 0.19 0.31 0.60 0.93 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Nutex Health Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ARDT Ardent Health, Inc. $2.2B 15.2× 12.8× +3.05% (above 0%: growing) n/m −23.49% (below 0%: shrinking) 100.00% 0.00% Compare
AGL Agilon Health, Inc. $1.9B — (loss-making) — (loss-making) +5.86% (above 0%: growing) n/m +234.38% (above 0%: growing) 0.00% 1.59% Compare
HCSG Healthcare Services Group, Inc. $1.7B 16.6× 18.6× +3.29% (above 0%: growing) −37.29% (below 0%: shrinking) −59.81% (below 0%: shrinking) 16.76% 6.66% Compare
SNDA Sonida Senior Living, Inc. $1.6B — (loss-making) — (loss-making) +114.40% (above 0%: growing) n/m +360.11% (above 0%: growing) 35.68% (9.27%) Compare
USPH U.S. Physical Therapy, Inc. $1.5B — (loss-making) 45.8× +12.90% (above 0%: growing) n/m +32.17% (above 0%: growing) 19.34% 0.00% Compare
PNTG The Pennant Group, Inc. $1.4B 37.3× 36.7× +31.96% (above 0%: growing) +55.56% (above 0%: growing) −3.19% (below 0%: shrinking) 13.34% 5.46% Compare
NUTX Nutex Health Inc. $1.3B 7.4× 7.3× −13.62% (below 0%: shrinking) n/m +19.44% (above 0%: growing) 67.04% 57.75%
INNV InnovAge Holding Corp. $1.2B 124× 20.9× +12.14% (above 0%: growing) +155.00% (above 0%: growing) +622.82% (above 0%: growing) 24.02% 7.61% Compare
CMPS COMPASS Pathways PLC Sponsored ADR $1.1B — (loss-making) — — n/m −44.62% (below 0%: shrinking) — 0.00% Compare
Median of peers $1.5B 27.0× 20.9× +12.14% +55.56% +14.49% 19.34% 0.80%

All 51 Medical Care Facilities stocks →

Pay and ownership Proxy statement filed 13 March 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.94m 4.60m 57.76
2024 1.16m 1.56m 11.12
2023 1.02m 1.02m 9.47

Ownership

Directors and executive officers, together 44.68%
Tom Vo, Chairman and CEO 32.57%
Topline Capital Management, LLC 9.86%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Nutex Health Inc. (NUTX) Latest News

6 Nov

Impact 3 · · MarketBeat transcript

5 Nov

Impact 3 · · PR Newswire

19 Oct

Impact 3 · · PR Newswire earnings

28 Sep

Impact 3 · · Zacks

24 Sep

Impact 4 ·
Impact 4 · · Simply Wall St.

22 Sep

Impact 3 · · PR Newswire

10 Sep

Impact 4 ·

27 Aug

Impact 3 ·

25 Aug

Impact 3 ·
Impact 3 ·

18 Aug

Impact 3 ·

14 Aug

Impact 4 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 · · MarketBeat transcript
Impact 3 · · Moby transcript

6 Aug

Impact 3 ·

7 Jul

Impact 3 ·

4 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · Simply Wall St.

1 May

Impact 4 · · MarketBeat
Impact 4 · · Moby

30 Apr

Impact 4 · · PR Newswire

11 Mar

Impact 4 · · GuruFocus.com

9 Mar

Impact 4 · · Simply Wall St.

6 Mar

Impact 4 · · MarketBeat
Impact 4 · · Moby
Impact 4 · · Simply Wall St.

5 Mar

Impact 4 · · PR Newswire

4 Feb

Impact 4 · · Insider Monkey
stockrow.com/NUTX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com